Systemic effects of vaginally administered estrogen therapy: A review

Female Pelvic Medicine and Reconstructive Surgery

Volumn 16, Issue 3, 2010, Pages 188-195

  Krause, Megan ^a   Wheeler II, Thomas L ^b   Richter, Holly E ^c   Snyder, Thomas E ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Estradiol; Estrone; Hormone therapy; Vaginal hormones

Indexed keywords

BREAST CANCER; ESTRADIOL; ESTRONE; HORMONE LEVELS; HORMONE THERAPY; LIPID PROFILE; LOCAL EFFECTS; MENOPAUSAL SYMPTOMS; WOMEN'S HEALTH INITIATIVE;

EID: 79952960249     PISSN: 21518378     EISSN: None     Source Type: Journal    
DOI: 10.1097/SPV.0b013e3181d7e86e     Document Type: Review

References (39)

1. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 1991;20:47-63.
2. Grady D, Ruebin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016-1037.
3. Rijpkema AH, van der Sanden AA, Ruijs AH. Effects of postmenopausal estrogen-progesterone therapy on serum lipids and lipoproteins: a review. Maturitas. 1990;12:259-285. (Pubitemid 20279933)
4. Adams MR, Kaplan JR, Manuck SB, et al. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys: lack of an effect of added progesterone. Arteriosclerosis. 1990;10:1051-1057.
5. Weiss NS, Ure CL, Ballard JH, et al. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med. 1980;303:1195-1198. (Pubitemid 11207583)
6. Gerhardsson de Verdier M, London S. Reproductive factors, exogenous female hormones, and colorectal cancer by subsite. Cancer Causes Control. 1992;3:355-360.
7. Stamper MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease: ten year follow-up from the Nurses' Health Study. New Engl J Med. 1991;325:756-762.
8. Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial [published correction: JAMA. 1995; 274:1676].
9. JAMA. 1995;273:199-208.
10. Hulley S, Grady D, Bush T, et al. Heart and Estrogen/ Progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605-613. (Pubitemid 28502636)
11. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary artery atherosclerosis. N Engl J Med. 2000;343:522-529. (Pubitemid 30650747)
12. Rossouw JE, Anderson GL, Prentice RL, et al. Risk and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333. (Pubitemid 34761611)
13. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349:523-534. (Pubitemid 36951364)
14. Wassentheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women. The Women's Health Initiative: a randomized trial. JAMA. 2003;289:2673-2684. (Pubitemid 37430138)
15. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA. 2003;289:3243-3253. (Pubitemid 37430077)
16. Grady D. Clinical practice: management of menopausal symptoms. Review. N Engl J Med. 2006;355:2338-2347. (Pubitemid 44837782)
17. Anderson GL, Judd HL, Kaunitz AM, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA. 2003;290:1739-1748. (Pubitemid 37430624)
18. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bonemineral density: the Women's Health Initiative randomized trial. JAMA. 2003;290:1729-1738. (Pubitemid 37430623)
19. Crandall C. Vaginal estrogen preparations: a review of safety and efficacy for vaginal atrophy. J Womens Health (Larchmt). 2002;11:857-877. (Pubitemid 36322425)
20. Ballagh SA. Vaginal hormone therapy for urogenital and menopausal symptoms. Semin Reprod Med. 2005;23:126-140. (Pubitemid 40604898)
21. Krause M, Wheeler T, Snyder T, et al. Local effects of vaginally administered estrogen therapy: a review. J Pelvic Med Surg. 2009;15:105-114.
22. Rigg LA, Hermann H, Yen SS. Absorption of estrogens from vaginal creams. N Engl J Med. 1978;298:195-197. (Pubitemid 8272278)
23. Mandel FP, Geola FL, Meldrum DR, et al. Biological effects of various doses of vaginally administered conjugated equine estrogens in postmenopausal women. J Clin Endocrinol Metab. 1983;57:133-139. (Pubitemid 13065457)
24. Dorr MB, Ranganath RP, et al. Plasma estradiol and estrone concentrations after oral and vaginal administration of conjugated estrogens in postmenopausal women with atrophic vaginitis. Poster presented at the 55th American College of Obstetrics and Gynecology. May 5-9, 2007.
25. Vagifem [package insert]. Princeton, NJ: Novo Nordisk, Inc. Available at: http://www.vagifem.com.
26. Tourgeman DE, Gentzchein E, Stanczyk FZ, et al. Serum and tissue hormone levels of vaginally and orally administered estradiol. Am J Obstet Gynecol. 1999;180:1480-1483. (Pubitemid 29293275)
27. Martin PL, Greaney MO, Burnier AM, et al. Estradiol, estrone, and gonadotropin levels after use of vaginal estradiol. Obstet Gynecol. 1984;63:441-444. (Pubitemid 14175003)
28. Yen SS, Martin PL, Burnier AM, et al. Circulating estradiol, estrone, and gonadotropin levels following the administration of orally active 17β-estradiol in postmenopausal women. J Clin Endocrinol Metab. 1975;40:518-521.
29. Speroff L; The United States VR Investigator Group. Efficacy and tolerability of a novel estradiol vaginal ring for relief of menopausal symptoms. Obstet Gynecol. 2003;102:823-834. (Pubitemid 37206420)
30. Foidart JM, Vervliet J, Buytaert P. Efficacy of sustained- release vaginal oestriol in alleviating urogenital and systemic climacteric complaints. Maturitas. 1991;13:99-107. (Level I).
31. Vartiainen J, Wahlstrom T, Nilsson CG. Effects and acceptability of a new 17 beta-oestradiol-releasing vaginal ring in the treatment of postmenopausal complaints. Maturitas. 1993;17:129-137.
32. American College of Obstetricians and Gynecologists Women's Health Care Physicians: vasomotor symptoms. Obstet Gynecol. 2004;(suppl 104):106S-117S.
33. Naessen T, Rodriguez Macias K, Lithell H. Serum lipid profile improved by ultra-low doses of 17β- estradiol in elderly women. J Clin Endocrinol Metab. 2001;86:2757-2762. (Pubitemid 32545735)
34. Cummings SR, Browner WS, Bauer D, et al; Study of Osteoporotic Fractures Research Group. Endogenous hormones and the risk of hip and vertebral fractures among older women. N Engl J Med. 1998;339:733-738. (Pubitemid 28417356)
35. Naessen T, Berglund L, Ulmsten U. Bone loss in elderly women prevented by ultralow doses of parenteral 17β-estradiol. Am J Obstet Gynecol. 1997;177:115-119. (Pubitemid 27327321)
36. Ponzone R, Biglia N, Jacomuzzi ME, et al. Vaginal oestrogen therapy after breast cancer: is it safe? Eur J Cancer. 2005;41:2673-2681. (Pubitemid 41607558)
37. Kendall A, Dowsett M, Folkerd E, et al. Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol. 2006;17:584-587.
38. Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2003:CD001500.
39. Weisberg E, Fraser IS, Mishell DR Jr, et al. The acceptability of a combined oestrogen/progestogen contraceptive vaginal ring. Contraception. 1995;51:39-44.